Topotecan Pharmacokinetic Characterization Study

Summary

A multi-center, open label, single dose Phase I pharmacokinetic (PK) characterization of weekly IV (intravenous) topotecan given at 4mg/m2. 15 patients will be evaluated.

Timeline

Start

2006-09-12

Primary completion

2007-08-09

Completion

2007-08-09

Publications

• Background Curtis KK, Hartney JT, Jewell RC, Park JW, Lebowitz PF, Griffin PP, Borad MJ, Fitch TR, Northfelt DW. A phase I study to characterize the safety, tolerability, and pharmacokinetics of topotecan at 4 mg/m2 administered weekly as a 30-minute intravenous infusion in patients with cancer. J Clin Pharmacol. 2010 Mar;50(3):268-75. doi: 10.1177/0091270009343699. Epub 2009 Oct 6.

Drugs

Indications